Krsnaa Diagnostics Ltd
Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.[1]
- Market Cap ₹ 3,020 Cr.
- Current Price ₹ 934
- High / Low ₹ 973 / 528
- Stock P/E 41.8
- Book Value ₹ 263
- Dividend Yield 0.27 %
- ROCE 10.1 %
- ROE 7.52 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 3.56 times its book value
- Promoter holding is low: 27.2%
- Company has a low return on equity of 10.5% over last 3 years.
- Dividend payout has been low at 12.8% of profits over last 3 years
- Debtor days have increased from 72.1 to 110 days.
- Working capital days have increased from 46.3 days to 131 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
36 | 57 | 108 | 147 | 258 | 396 | 455 | 464 | 590 | 653 | |
35 | 42 | 169 | 87 | 373 | 302 | 320 | 340 | 444 | 479 | |
Operating Profit | 0 | 15 | -62 | 60 | -114 | 94 | 135 | 124 | 146 | 174 |
OPM % | 1% | 26% | -57% | 41% | -44% | 24% | 30% | 27% | 25% | 27% |
3 | 4 | 3 | 2 | 13 | 265 | 15 | 19 | 17 | 20 | |
Interest | 6 | 6 | 8 | 16 | 25 | 26 | 18 | 8 | 16 | 23 |
Depreciation | 5 | 10 | 18 | 26 | 32 | 37 | 41 | 54 | 75 | 80 |
Profit before tax | -7 | 2 | -84 | 21 | -158 | 295 | 90 | 82 | 72 | 91 |
Tax % | 6% | 8% | -29% | 40% | -29% | 37% | 21% | 23% | 19% | |
-8 | 2 | -60 | 12 | -112 | 185 | 71 | 64 | 59 | 72 | |
EPS in Rs | -15.05 | 4.01 | -116.54 | 24.15 | -216.83 | 284.73 | 22.52 | 20.23 | 18.14 | 22.34 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 11% | 14% | 14% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 32% |
3 Years: | 14% |
TTM: | 28% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 36% |
3 Years: | -32% |
TTM: | 31% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 14% |
1 Year: | 49% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 11% |
Last Year: | 8% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 5 | 5 | 5 | 5 | 6 | 16 | 16 | 16 | 16 |
Reserves | 4 | 6 | 43 | -217 | -17 | 671 | 727 | 799 | 833 |
131 | 102 | 330 | 246 | 474 | 41 | 32 | 160 | 216 | |
24 | 63 | 115 | 596 | 146 | 149 | 134 | 197 | 230 | |
Total Liabilities | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 | 1,295 |
59 | 116 | 223 | 275 | 309 | 386 | 471 | 647 | 689 | |
CWIP | 20 | 6 | 42 | 9 | 4 | 28 | 25 | 10 | 3 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
85 | 53 | 228 | 345 | 297 | 463 | 413 | 514 | 602 | |
Total Assets | 163 | 176 | 493 | 630 | 609 | 877 | 909 | 1,172 | 1,295 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
59 | 61 | 38 | 119 | 129 | 75 | 24 | |||
-53 | -201 | -77 | -67 | -241 | -109 | -129 | |||
-37 | 145 | 6 | 20 | 176 | -33 | 84 | |||
Net Cash Flow | -31 | 4 | -33 | 71 | 64 | -66 | -20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 87 | 91 | 140 | 87 | 69 | 48 | 59 | 110 | |
Inventory Days | 21 | 24 | 89 | ||||||
Days Payable | 76 | 99 | 878 | ||||||
Cash Conversion Cycle | 32 | 15 | -650 | 87 | 69 | 48 | 59 | 110 | |
Working Capital Days | 57 | -43 | -100 | -3 | -23 | -14 | 22 | 131 | |
ROCE % | 7% | -65% | 129% | 18% | 12% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Announcement of analyst/investor meeting on November 22, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Investor meeting scheduled for November 12, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8 Nov - -Analyst / Institutional Investor Meeting scheduled to be held on November 11, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Nov - -Analyst / Institutional Investor Meeting scheduled to be held on November 07, 2024.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
5 Nov - Transcript of Q2 FY '25 earnings call released.
Annual reports
Concalls
-
Nov 2024Transcript PPT
-
Oct 2024TranscriptNotesPPT
-
Aug 2024Transcript PPT
-
Aug 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT REC
-
Jun 2022Transcript PPT
-
Mar 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021TranscriptPPT
-
Oct 2021Transcript PPT
Service Offerings
The company is one of India’s fastest‑growing, differentiated diagnostics service providers. Its technology-enabled diagnostic services include imaging (including radiology), pathology/clinical laboratory, and tele‑radiology services. It has proven capabilities and the largest presence in the PPP diagnostics segment and extends its services to private and public hospitals, medical colleges, and community health centers in Pan‑India. [1]